You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Boehringer Ingelheim
Moodys
Express Scripts
McKinsey

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Patent: 7,541,328

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,541,328
Title:Coupling proteins to a modified polysaccharide
Abstract: The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.
Inventor(s): Hemberger; Jurgen (Aschaffenburg, DE), Orlando; Michele (The Hague, NL), Sommermeyer; Klaus (Rosbach v.d.H, DE), Eichner; Wolfram (Butzbach, DE), Frie; Sven (Bramois, CH), Lutterbeck; Katharina (Friedberg, DE), Jungheinrich; Cornelius (Bad Homburg, DE), Scharpf; Roland (Ranstadt, DE)
Assignee: Fresenius Kabi Deutschland GmbH (Bad Homburg v.d.H, DE)
Application Number:10/506,367
Patent Claims:see list of patent claims

Details for Patent 7,541,328

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Fresenius Kabi Deutschland GmbH (Bad Homburg v.d.H, DE) 2022-03-06 RX search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial Fresenius Kabi Deutschland GmbH (Bad Homburg v.d.H, DE) 2022-03-06 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial Fresenius Kabi Deutschland GmbH (Bad Homburg v.d.H, DE) 2022-03-06 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Harvard Business School
Johnson and Johnson
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.